Fintel reports that on January 28, 2026, Barclays initiated coverage of Ascendis Pharma A (NasdaqGS:ASND) with a Overweight recommendation.
Analyst Price Forecast Suggests 13.92% Upside
As of January 14, 2026, the average one-year price target for Ascendis Pharma A is $272.05/share. The forecasts range from a low of $227.25 to a high of $341.25. The average price target represents an increase of 13.92% from its latest reported closing price of $238.80 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Ascendis Pharma A is 1,388MM, an increase of 114.68%. The projected annual non-GAAP EPS is -9.07.
What is the Fund Sentiment?
There are 526 funds or institutions reporting positions in Ascendis Pharma A. This is an decrease of 4 owner(s) or 0.75% in the last quarter. Average portfolio weight of all funds dedicated to ASND is 0.77%, an increase of 1.98%. Total shares owned by institutions decreased in the last three months by 2.50% to 77,373K shares. 
The put/call ratio of ASND is 0.32, indicating a bullish outlook.
What are Other Shareholders Doing?
Ra Capital Management holds 10,281K shares. No change in the last quarter.
Westfield Capital Management Co holds 5,260K shares. In its prior filing, the firm reported owning 5,451K shares , representing a decrease of 3.64%. The firm increased its portfolio allocation in ASND by 11.19% over the last quarter.
Avoro Capital Advisors holds 5,110K shares. In its prior filing, the firm reported owning 4,980K shares , representing an increase of 2.54%. The firm decreased its portfolio allocation in ASND by 12.76% over the last quarter.
Janus Henderson Group holds 4,323K shares. In its prior filing, the firm reported owning 4,428K shares , representing a decrease of 2.42%. The firm decreased its portfolio allocation in ASND by 59.65% over the last quarter.
Artisan Partners Limited Partnership holds 3,721K shares. In its prior filing, the firm reported owning 3,990K shares , representing a decrease of 7.24%. The firm increased its portfolio allocation in ASND by 4.07% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
